& Chaiyakunapruk, N
Not for a few years yet Drug Discovery and Development, accessed February 2, 2026, Patent Term Extension Considerations For Regulated Products | Sterne Kessler, accessed February 2, 2026, The Heavy Price of GLP-1 Drugs: How Financialization Drives Pharmaceutical Patent Abuse and Health Inequities for GLP-1 Therapies I-MAK, accessed February 2, 2026, Global GLP-1 Market Size, Forecast & Growth Industry 2035 Roots Analysis, accessed February 2, 2026, Part III The Battleground: Chinas Biotech Shift in Cardiometabolics and the GLP-1 Gravity Well GeneOnline, accessed February 2, 2026, When do the patents on OZEMPIC expire, and when will OZEMPIC , accessed February 2, 2026, ANALYSIS: Price wars cloud the GLP-1 obesity drug boom once forecast at $150bn, accessed February 2, 2026, Market Overview: GLP-1 Agonists and the Obesity Market | Blog Ozmosi, accessed February 2, 2026, Lilly, Novo Skew Overall Pharma Trends With Colossal GLP-1 Sales Growth BioSpace, accessed February 2, 2026, Outlook for Obesity in 2026: From Consolidation to Acceleration | IQVIA, accessed February 2, 2026, The Hatch-Waxman Act: A Primer EveryCRSReport.com, accessed February 2, 2026, Global Exclusivity Divergence: Hatch-Waxman PTE Versus , accessed February 2, 2026, Counting Patents, Not Progress: Another Misdiagnosis by I-MAK IPWatchdog.com, accessed February 2, 2026, Republican Administration Maintains Exclusivity Stance in GLP-1 (Tirzepatide) Compounding Dispute | Patently-O, accessed February 2, 2026, Rybelsus patent expiration Pharsight GreyB, accessed February 2, 2026, The Role of Patents and Regulatory Exclusivities in Drug Pricing | Congress.gov, accessed February 2, 2026, Early impact of the Inflation Reduction Act on small molecule vs biologic post-approval oncology trials PMC NIH, accessed February 2, 2026, Ozempic, Wegovy and Rybelsus: The patents behind Novo Nordisks weight-loss drugs, accessed February 2, 2026, What is the patent landscape for Novo Nordisks semaglutide , accessed February 2, 2026, Viatris beats Novo in semaglutide patent feud, clearing hurdle for potential Wegovy generic, accessed February 2, 2026, When do the patents on RYBELSUS expire, and when will RYBELSUS go generic
Shared signaling pathways, complementary effects on inflammation and oxidative stress, coordinated neuroprotection, and mutually reinforcing influences on body composition all point in the same direction
For instance, in November 2023, results from the SELECT trial published in the New England Journal of Medicine showed that once-weekly semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease without diabetes, highlighting the expanding role of long-acting GLP-1 analogues beyond glycemic control into cardiovascular risk reduction
